Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Open-Label, Randomized Study Comparing GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy Including Lenalidomide and Proteasome Inhibitors
Conditions
Interventions
GR1803 injection
Daratumumab
+2 more
Locations
1
China
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, China
Start Date
March 9, 2026
Primary Completion Date
March 1, 2029
Completion Date
March 1, 2030
Last Updated
March 25, 2026
NCT06679101
NCT05969860
NCT06057402
NCT06870760
NCT06383143
NCT05243797
Lead Sponsor
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions